Alcoholic liver disease (also called alcohol-related liver disease) is a spectrum of liver injury caused by chronic alcohol overconsumption, including fatty liver, alcoholic hepatitis, fibrosis, and cirrhosis. Disease severity can progress over time without alcohol abstinence.
GSK agreed to license linerixibat to Alfasigma in a deal worth up to $690 million, while Eisai received orphan drug designation in Japan for E2086, a novel selective orexin 2 receptor agonist for narcolepsy.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06307964 |
Intra-Hepatic Microbiota in Alcoholic Hepatitis |
RECRUITING | |
| NCT05895890 |
French National MICMAF Cohort |
RECRUITING | |
| NCT05855031 |
The Liver Care Trial |
RECRUITING | NA |
| NCT05793190 |
Gut Mycobiome Profile in Alcoholic Liver Disease. |
UNKNOWN | |
| NCT05473325 |
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) |
UNKNOWN | |
| NCT05428072 |
Alcohol, Gut Leakiness, & Liver Disease |
COMPLETED | EARLY_PHASE1 |
| NCT05007470 |
Alcoholic Liver Disease and the Gut Microbiome |
ACTIVE_NOT_RECRUITING | NA |
| NCT04858412 |
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19 |
RECRUITING | NA |
| NCT04736966 |
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease |
COMPLETED | PHASE1 |
| NCT04666402 |
Integrated Diagnostics for Early Diagnosis of Liver Disease |
RECRUITING |
